Sep 30 |
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
|
Sep 29 |
Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
|
Sep 29 |
Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent set to advance in top drug sales
|
Sep 29 |
Regeneron: Long-Term Defensive Investment
|
Sep 28 |
Regeneron, Sanofi announce Dupixent approval in China for patients with COPD
|
Sep 28 |
Wall Street Breakfast: What Moved Markets
|
Sep 28 |
Jim Cramer on Regeneron Pharmaceuticals Inc. (REGN): ‘Leerink Analysts Downgraded Regeneron To A Market Perform Hold After A Negative Eylea 2mg Biosimilar Preliminary Injunction Ruling’
|
Sep 27 |
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
|
Sep 27 |
Regeneron Shares Head for Worst Month Since 2019 on Legal Ruling
|
Sep 27 |
FDA greenlights Regeneron’s Dupixent for the treatment of COPD
|